These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A practical guide to the management of distal ulcerative colitis. Ardizzone S; Bianchi Porro G Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342 [TBL] [Abstract][Full Text] [Related]
5. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Bello C; Belaiche J; Louis E; Reenaers C J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881 [TBL] [Abstract][Full Text] [Related]
6. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262 [TBL] [Abstract][Full Text] [Related]
8. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445 [TBL] [Abstract][Full Text] [Related]
9. Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis. Hyams JS; Brimacombe M; Haberman Y; Walters T; Gibson G; Mo A; Mack D; Griffiths A; Boyle B; LeLeiko N; Markowitz J; Rosh J; Patel A; Shah S; Baldassano R; Pfefferkorn M; Sauer C; Dailey J; Venkateswaran S; Kugathasan S; Denson LA Inflamm Bowel Dis; 2022 Feb; 28(2):151-160. PubMed ID: 33904583 [TBL] [Abstract][Full Text] [Related]
10. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. Zeisler B; Lerer T; Markowitz J; Mack D; Griffiths A; Bousvaros A; Keljo D; Rosh J; Evans J; Kappelman M; Otley A; Kay M; Grossman A; Saeed S; Carvalho R; Oliva-Hemker M; Faubion W; Sudel B; Pfefferkorn M; Ashai-Khan F; Leleiko N; Hyams J; J Pediatr Gastroenterol Nutr; 2013 Jan; 56(1):12-8. PubMed ID: 22847466 [TBL] [Abstract][Full Text] [Related]
11. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Turner D; Mack D; Leleiko N; Walters TD; Uusoue K; Leach ST; Day AS; Crandall W; Silverberg MS; Markowitz J; Otley AR; Keljo D; Mamula P; Kugathasan S; Hyams J; Griffiths AM Gastroenterology; 2010 Jun; 138(7):2282-91. PubMed ID: 20193683 [TBL] [Abstract][Full Text] [Related]
12. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356 [TBL] [Abstract][Full Text] [Related]
15. High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. Winter HS; Krzeski P; Heyman MB; Ibarguen-Secchia E; Iwanczak B; Kaczmarski M; Kierkus J; Kolaček S; Osuntokun B; Quiros JA; Shah M; Yacyshyn B; Dunnmon PM J Pediatr Gastroenterol Nutr; 2014 Dec; 59(6):767-72. PubMed ID: 25419597 [TBL] [Abstract][Full Text] [Related]
16. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. Jeon HH; Lee HJ; Jang HW; Yoon JY; Jung YS; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH World J Gastroenterol; 2013 Jan; 19(2):265-73. PubMed ID: 23345950 [TBL] [Abstract][Full Text] [Related]
18. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063 [TBL] [Abstract][Full Text] [Related]
19. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
20. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R; Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]